Chemomab Therapeutics Ltd. American Depositary Share (CMMB)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Chemomab is not the kind of business Graham would have bought on the numbers. It is a clinical-stage biotechnology company with no revenue in the filed figures. Its losses have been growing: in fiscal 2020 net loss was $6.0M, in fiscal 2021 $12.5M, and in fiscal 2022 $27.6M. In fiscal Q1 2023, the quarter ended 2023-03-31, the net loss was $8.8M, so the burn continued at a high rate. There is no useful earnings multiple; the P/E is negative at -1.19 at the 2026-10-13 close. The P/B of 1.03 and market cap of $11.9M tell us the market is valuing it near book, but book value is not a productive asset base; it is likely funding the trials. The FairStock Piotroski F-Score is 0/9 and the Altman Z-Score is -10.23, which are distress and weak-quality signals. The only real asset is the pipeline: nebokitug, described in the filing as a humanized monoclonal antibody with Phase 2 completed in primary sclerosing cholangitis and Phase 2 in another systemic condition. That is a lottery-ticket profile: binary clinical risk, no moat yet, and dependent on external capital. A beta of 0.74 and a FairStock Score of 64/100 may suggest some moderation, but they do not offset four years of losses and a 0/9 Piotroski. At $1.24, the price is low, but low is not the same as cheap when the company must still prove efficacy and raise money. I would want to see trial data and a cleaner balance sheet before calling this a value opportunity.

In plain English: Chemomab Therapeutics is a small drug company testing an experimental medicine for scarring and inflammatory diseases. It has no reported product sales and has lost money for years, so the underlying business looks weak and unproven. At $1.24 a share, the price is very low, but it is not clearly a bargain because the company still must prove its main drug works and fund those tests.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2023 10-Q (period ended 2023-03-31) · fiscal Q3 2022 10-Q (period ended 2022-09-30) · fiscal Q2 2022 10-Q (period ended 2022-06-30) · fiscal Q1 2022 10-Q (period ended 2022-03-31) · FY2022 10-K (period ended 2022-12-31) · FY2021 10-K (period ended 2021-12-31) · FY2020 10-K (period ended 2020-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer